ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion
Immunity, Inflammation and Disease · 2026
DOI: 10.1002/iid3.70496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Hui Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Biobank, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Alkaline Phosphatase, Arachidonic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Plan, Guangdong Province Grant for Belt and Road Joint Laboratory, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Background
Asialoglycoprotein receptor 1 (ASGR1), a hepatocyte‐specific receptor, represents a potential therapeutic target for hypercholesterolemia. However, liver safety risks of ASGR1‐targeted therapies remain poorly characterized. This study aims to investigate the impact of ASGR1 deficency on liver fibrosis and its underlying mechanisms.
Methods
ASGR1 knockout (ASGR1 −/− ) mice and wild‐type controls were subjected to carbon tetrachloride (CCl 4 ) administration or bile duct ligation (BDL) to induce liver fibrosis. Serum biomarkers, including alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), were measured. Transcriptomic analysis was performed to identify altered pathways. Primary mouse hepatocytes, HepG2 cells, and hepatic stellate cells (HSCs) were used for in vitro mechanistic validation.
Results
ASGR1 deficiency significantly exacerbates liver fibrosis in both CCl 4 ‐ and BDL ‐induced models and specifically induces an increase in serum alkaline phosphatase (ALP), which showed greater sensitivity than alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Mechanistic studies showed that ASGR1 loss led to a significant increase in the transcription and secretion of hepatic ALP. Transcriptomic analysis revealed that ASGR1 knockout mice not only disrupted bile acid metabolism but also upregulated the synthesis of arachidonic acid metabolites (e.g., PTGES, a key enzyme involved in pro‐inflammatory eicosanoid synthesis) and the pro‐fibrotic factor TGFβ1, collectively accelerating fibrosis. Importantly, Supernatants from ASGR1 −/− primary mouse hepatocytes and HepG2 cells, as well as exogenous ALP, directly activated hepatic stellate cells (HSCs), promoting their activation and α‐SMA expression.
Conclusions
ASGR1 deficiency aggravates liver fibrosis, which is likely mediated through the “ASGR1‐arachidonic acid‐ALP” axis that enhances pro‐inflammatory eicosanoid production and ALP secretion. These findings highlight the liver‐specific safety risk of ASGR1 as a therapeutic target for lipid disorders and provide mechanistic and translational references for clinical safety monitoring of ASGR1‐targeted drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Biobank, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing,…
- Clinical Biobank, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
- State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
- Institute of Development and Regeneration, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Institute of Biological and Medical Engineering, Guangdong Academy of Sciences, Guangzhou, China.
ORCID-Profile: Hui Zhu, Xin-Ping Huang, Kai You, Yan Chen, Peng-Hui Li, Jia-Wang Tao, Xiao-Rui Yu, Jie-Hui Xu, Guo-Sheng Xu, Yin-Xiong Li
Förderung
- National Key Research and Development Plan
- Guangdong Province Grant for Belt and Road Joint Laboratory
- Guangdong Basic and Applied Basic Research Foundation
- Guangzhou Science and Technology plan project
- Basic Research Project of Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science
- China-New Zealand Joint Laboratory on Biomedicine and Health
Zitieren
APA
Zhu, H., Huang, X. P., You, K., Chen, Y., Li, P. H., Tao, J. W., Yu, X. R., Xu, J. H., Xu, G. S., & Li, Y. X. (2026). ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70496
Vancouver
Zhu H, Huang XP, You K, Chen Y, Li PH, Tao JW, et al. ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70496
BibTeX
@article{Zhu2026,
author = {Zhu, Hui and Huang, Xin-Ping and You, Kai and Chen, Yan and Li, Peng-Hui and Tao, Jia-Wang and Yu, Xiao-Rui and Xu, Jie-Hui and Xu, Guo-Sheng and Li, Yin-Xiong},
title = {ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion},
journal = {Immunity, Inflammation and Disease},
year = {2026},
doi = {10.1002/iid3.70496}
}
EUVIMED